Petros Pharmaceuticals, Inc.

NasdaqCM:PTPI Stock Report

Market Cap: US$2.9m

Petros Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Fady Boctor

Chief executive officer

US$875.1k

Total compensation

CEO salary percentage40.0%
CEO tenure4.9yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure4yrs

Recent management updates

It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Nov 13
It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Recent updates

It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Nov 13
It's Probably Less Likely That Petros Pharmaceuticals, Inc.'s (NASDAQ:PTPI) CEO Will See A Huge Pay Rise This Year

Petros Pharmaceuticals GAAP EPS of -$0.10, revenue of $6.6M

Aug 15

Petros Pharma shares more than triple in value after co to be taken private in $67.2M deal

Jul 28

Petros Pharmaceuticals: Advancing Complementary Men's Health Therapeutics

Dec 07

CEO Compensation Analysis

How has Fady Boctor's remuneration changed compared to Petros Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024n/an/a

-US$20m

Jun 30 2024n/an/a

-US$21m

Mar 31 2024n/an/a

-US$20m

Dec 31 2023US$875kUS$350k

-US$14m

Sep 30 2023n/an/a

-US$14m

Jun 30 2023n/an/a

-US$22m

Mar 31 2023n/an/a

-US$21m

Dec 31 2022US$682kUS$350k

-US$20m

Sep 30 2022n/an/a

-US$24m

Jun 30 2022n/an/a

-US$12m

Mar 31 2022n/an/a

-US$12m

Dec 31 2021US$1mUS$350k

-US$9m

Sep 30 2021n/an/a

-US$6m

Jun 30 2021n/an/a

-US$8m

Mar 31 2021n/an/a

-US$11m

Dec 31 2020US$468kUS$276k

-US$21m

Sep 30 2020n/an/a

-US$24m

Jun 30 2020n/an/a

-US$29m

Mar 31 2020n/an/a

-US$32m

Dec 31 2019US$340kUS$208k

-US$33m

Compensation vs Market: Fady's total compensation ($USD875.10K) is above average for companies of similar size in the US market ($USD653.16K).

Compensation vs Earnings: Fady's compensation has increased whilst the company is unprofitable.

CEO

Fady Boctor (46 yo)

4.9yrs

Tenure

US$875,096

Compensation

Mr. Fady Boctor, MBA, has been the President and Chief Commercial Officer of Petros Pharmaceuticals, Inc. since 2020. Mr. Boctor has experience in the pharmaceutical industry, across a wide array of functi...

Board Members

NamePositionTenureCompensationOwnership
Joshua Silverman
Independent Chairman of the Board4yrsUS$309.30k0.11%
$ 3.3k
Wayne Walker
Independent Director4yrsUS$147.97k0.083%
$ 2.4k
Bruce Bernstein
Independent Director4yrsUS$147.97k0.083%
$ 2.5k

4.0yrs

Average Tenure

61yo

Average Age

Experienced Board: PTPI's board of directors are considered experienced (4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 07:41
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Petros Pharmaceuticals, Inc. is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Nazibur RahmanMaxim Group